Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to -$107.3 million.

  • Denali Therapeutics' Cash from Operations fell 8143.02% to -$107.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.8 million, marking a year-over-year decrease of 969.04%. This contributed to the annual value of -$347.7 million for FY2024, which is 287.63% up from last year.
  • Denali Therapeutics' Cash from Operations amounted to -$107.3 million in Q3 2025, which was down 8143.02% from -$75.3 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Cash from Operations registered a high of -$41.4 million during Q3 2021, and its lowest value of -$131.5 million during Q1 2025.
  • For the 5-year period, Denali Therapeutics' Cash from Operations averaged around -$77.7 million, with its median value being -$72.7 million (2022).
  • As far as peak fluctuations go, Denali Therapeutics' Cash from Operations tumbled by 4827906.98% in 2021, and later skyrocketed by 3230.66% in 2024.
  • Denali Therapeutics' Cash from Operations (Quarter) stood at -$65.5 million in 2021, then dropped by 10.95% to -$72.7 million in 2022, then tumbled by 35.77% to -$98.7 million in 2023, then increased by 15.15% to -$83.7 million in 2024, then dropped by 28.17% to -$107.3 million in 2025.
  • Its Cash from Operations stands at -$107.3 million for Q3 2025, versus -$75.3 million for Q2 2025 and -$131.5 million for Q1 2025.